STAMFORD, CT / ACCESSWIRE / August 28, 2023 / Abbott Cooper PLLC is investigating Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or the "Company") on behalf of the Company's investors.
The investigation seeks to determine whether Atea stockholders have been injured due to any violations of fiduciary duty or federal securities law in connection with (i) Atea's rejection of Tang Capital Partners' offer, made on behalf of Concentra Biosciences, to acquire all outstanding shares of Atea common stock for $5.75 plus a contingent value right and (ii) changes to Atea's advance notice bylaws that may chill or prevent attempts by Atea stockholders to hold the Atea board accountable for failing to increase stockholder value.
Atea stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders' rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
Abbott Cooper PLLC
J. Abbott R. Cooper, Esq.
Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Abbott Cooper PLLC